ArticleJournal of hematology & oncology2025

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.

Brian J Ball et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.